This review discusses the rationale behind molecular testing of patients with advanced NSCLC, highlights the benefits of comprehensive genomic profiling at diagnosis and presents four cases that demonstrate the need for tissue stewardship in the context of biomarker testing.

The dynamic nature of the immune tumor microenvironment presents challenges for robust biomarker development for immunotherapy.

In this real-world study of patients with advanced NSCLC treated with immune checkpoint inhibitors, integrated analysis of ctDNA and matched white blood cells measured molecular response through longitudinal liquid biopsy and more accurately predicted radiographic response and overall survival.

Contrived samples, prepared from cell line derived DNA and cell line derived DNA spiked into non-cancerous cfDNA plasma to mimic the features of cfDNA, facilitates robust testing of rare variants in clinical samples and further supports analytical validation studies.

PGDx elio^TM plasma focus assesses cell-free DNA (cfDNA) to enable non-invasive genomic profiling with next-generation sequencing. This study characterized a range of pre-analytic factors including cfDNA fraction and yield across 293 clinical plasma samples.

In a discovery cohort of 24,186 solid tumors across 35 tumor histologies, comprehensive immune profiling assay using the OmniSeq® INSIGHT assay demonstrated significant co-expression of HIF-1α with downstream genes, especially those related to angiogenesis and novel gene signatures that characterize the hypoxic tumor microenvironment.

Using comprehensive genomic and immune profiling on discovery cohort of 24,186 solid tumors across 35 tumor types, this study confirmed that TIGIT expression is correlated with PD-L1 expression. Patients whose tumors express higher levels of TIGIT and PD-L1 via immunohistochemistry had improved overall survival.